CMML Prognostic Scoring Systems (from Spain and Dusseldorf)
Assess risk of progression to AML and early mortality in CMML
CMML is a stem cell disorder with heterogeneous clinical and pathologic features, often sharing characteristics of both myelodysplastic and myeloproliferative disorders. This study of 235 individuals registered in a German MDS Registry determined prognostic findings associated with overall survival and transformation to acute myeloid leukemia, specific to CMML. The authors identified 4 factors that were able to differentiate patients into 3 risk categories with expectant median survivals ranging from 11 months to 93 months. An alternative scoring system (from the Spanish Registry) is an option when cytogenetic studies are available.
- [1]Such E, Cervera J, Nomdedeu B, Pedro C, Bueno J, et al.: A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia. American Society of Hematology. New Orleans: Blood; 2009:abstract # 1750.
- [2]Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W.: Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.Leukemia 1992, 6 (1): 52-9
Results
Real-time automated computation
CMML is a stem cell disorder with heterogeneous clinical and pathologic features, often sharing characteristics of both myelodysplastic and myeloproliferative disorders. This study of 235 individuals registered in a German MDS Registry determined prognostic findings associated with overall survival and transformation to acute myeloid leukemia, specific to CMML. The authors identified 4 factors that were able to differentiate patients into 3 risk categories with expectant median survivals ranging from 11 months to 93 months. An alternative scoring system (from the Spanish Registry) is an option when cytogenetic studies are available.
- [1]Such E, Cervera J, Nomdedeu B, Pedro C, Bueno J, et al.: A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia. American Society of Hematology. New Orleans: Blood; 2009:abstract # 1750.
- [2]Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W.: Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.Leukemia 1992, 6 (1): 52-9